K(
Therapeutic Areas
MeiraGTx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| botaretigene sparoparvovec (bota-vec, AAV-RPGR) | X-linked retinitis pigmentosa (XLRP) | Phase 3 |
| AAV-CNGB3 | Achromatopsia (CNGB3-associated) | Phase 1/2 |
| AAV-CNGA3 | Achromatopsia (CNGA3-associated) | Phase 1/2 |
| AAV-AQP1 | Radiation-induced xerostomia | Phase 1 |
| AAV-GAD | Parkinson's Disease | Preclinical/Phase 1 |
| AAV-UPF1 | Amyotrophic Lateral Sclerosis (ALS) | Preclinical |
Leadership Team at MeiraGTx
AF
Alexandria Forbes, Ph.D.
President, Chief Executive Officer, and Director
RG
Richard Giroux
Chief Operating Officer and Chief Financial Officer
MS
M. Scott Salka
Chief Business Officer
NM
Natalie Mount, Ph.D.
Executive Vice President, Program & Portfolio Management
MD
Michele DiMascio, Ph.D.
Senior Vice President, Head of Manufacturing
JW
John W. Smither
Senior Vice President, Chief Financial Officer (former)
ZF
Zandy Forbes, Ph.D.
Founder and Director
PF
Patrick F. Terry
Director
RJ
Robert J. (Bob) Iannone, M.D., M.S.C.E.
Director (Executive Vice President, Head of R&D, Janssen)
J(
James (Jay) M. Wilson, Ph.D.
Director (Scientific Founder)